Jan Alsner
(Aarhus University Hospital)
18/10/2012, 17:15
Modulation of Radiosensitivity
oral (invited speaker)
Hypoxic tumours are associated with increased resistance to radiotherapy. In head and neck squamous cell carcinomas (HNSCC), this resistance can be counteracted via addition of hypoxic modification to the radiotherapy. Tumours are heterogeneous with respect to the degree and extend of hypoxia, and several methods have been developed to detect relevant tumour hypoxia. These include direct...
Prof.
Udo Gaipl
(Department of Radiation Oncology, University Hospital Erlangen)
18/10/2012, 17:45
Modulation of Radiosensitivity
oral (invited speaker)
Hyperthermia (HT) has been shown in various cell culture, preclinical animal and clinical models to be a very potent radio- and chemosensitizer. Recent research suggests that local heating (41-43°C for 1 hour) of the tumour may lead to abscopal, systemic and immune stimulatory effects, since cancer cells can be rendered visible to the immune system by standard therapies either alone or in...
Dr
Nina F. Jeppesen Edin
(University of Oslo)
18/10/2012, 18:15
Modulation of Radiosensitivity
oral (20 minutes)
We have previously found that protracting a priming dose of 0.3 Gy over 1 hour resulted in permanent elimination of low dose hyper radio-sensitivity (HRS) instead of the transient elimination by an acute priming with the same dose. The cells exposed to the low dose-rate priming secreted a factor into the medium, which removed HRS transiently in recipient cells. The factor could also be induced...
Dr
Clarice Patrono
(ENEA C.R. CASACCIA, Rome, Italy)
18/10/2012, 18:35
Modulation of Radiosensitivity
oral (20 minutes)
Clarice Patrono1, Laura Verna2, Silvia Sterpone3, Valentina Palma1, Renata Cozzi3, Antonella Testa1
1ENEA Casaccia, Rome, Italy; 2S. Pietro Hospital, Radiotherapy Unit, Rome Italy; 3Department of Biology, “Roma Tre” University, Rome, Italy
Therapeutic exposure to ionizing radiation can induce normal tissue side effects which consistently differ among individuals suggesting a possible...
Mr
Sylvain FERRANDON
(EMR3738-Cellular and Molecular Radiobiology Laboratory)
18/10/2012, 18:55
Modulation of Radiosensitivity
oral (20 minutes)
Despite a standard of care combining surgery, radiotherapy (RT) and Temozolomide chemotherapy, average. Glioblastoma patient survival is still less than one year. However, recent advances in molecular signalization profiling in glioblastoma have provided new targets for personalized medicine development and new irradiation techniques, such as carbon ion Hadrontherapy, are now available. The...
